Literature DB >> 28316531

Review.

Eric R Kallwitz1.   

Abstract

Year:  2006        PMID： 28316531      PMCID： PMC5350256     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  25 in total

1.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Authors:  Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Kentaro Yoshioka; Hirohito Tsubouchi; Kendo Kiyosawa; Shinichi Kakumu; Kiwamu Okita; Norio Hayashi; Takeshi Okanoue
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

Review 2.  AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.

Authors:  Mark Bower; Carlo Palmieri; Tony Dhillon
Journal:  Curr Opin Infect Dis       Date:  2006-02       Impact factor: 4.915

Review 3.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy.

Authors:  Takahiro Yamaura; Akihiro Matsumoto; Akinori Rokuhara; Tetuya Ichijo; Ehji Tanaka; Kazuhiro Hanazaki; Shoji Kajikawa; Kendo Kiyosawa
Journal:  J Gastroenterol Hepatol       Date:  2002-11       Impact factor: 4.029

5.  Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Authors:  Yasushi Shiratori; Shuichiro Shiina; Takuma Teratani; Masatoshi Imamura; Shun'taro Obi; Shin'pei Sato; Yukihiro Koike; Haruhiko Yoshida; Masao Omata
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

6.  Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

Authors:  Takeshi Okanoue; Masahito Minami; Akiko Makiyama; Yoshio Sumida; Kohichiroh Yasui; Yoshito Itoh
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

Review 7.  Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Authors:  Masao Omata; Haruhiko Yoshida; Yasushi Shiratori
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

8.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

9.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.